Roberta DAmbrosio
Overview
Explore the profile of Roberta DAmbrosio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caviglia G, DAmbrosio R, Colombatto P, Ciancio A
Aliment Pharmacol Ther
. 2024 Dec;
61(3):585-586.
PMID: 39723756
No abstract available.
2.
Caviglia G, Fariselli P, DAmbrosio R, Colombatto P, Degasperi E, Ricco G, et al.
Aliment Pharmacol Ther
. 2024 Nov;
61(3):538-549.
PMID: 39569574
Background And Aims: Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein...
3.
Rosato V, Nevola R, Dallio M, Di Micco P, Spinetti A, Zeneli L, et al.
J Clin Med
. 2024 Oct;
13(19).
PMID: 39407867
Direct oral anticoagulants (DOACs) are recommended for the management of thrombosis prophylaxis, especially in patients with atrial fibrillation. As substrates of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein, they are implicated...
4.
Micheli L, Pacini A, Di Cesare Mannelli L, Trallori E, DAmbrosio R, Bianchini C, et al.
Nutrients
. 2024 Jul;
16(13).
PMID: 38999922
In the original publication [...].
5.
DAmbrosio R, Anolli M, Pugliese N, Masetti C, Aghemo A, Lampertico P
Liver Int
. 2024 May;
44(7):1548-1563.
PMID: 38804727
In 2016, the Global Health Sector Strategy, ratified by the 69th World Health Assembly, set the ambitious goal of eliminating hepatitis C virus (HCV) and hepatitis B virus infections by...
6.
Quaranta M, Cavalletto L, Russo F, Calvaruso V, Ferrigno L, Zanetto A, et al.
Viruses
. 2024 May;
16(5).
PMID: 38793565
The treatment of hepatitis C virus (HCV) with direct-acting antivirals (DAA) leads to high sustained virological response (SVR) rates, but hepatocellular carcinoma (HCC) risk persists in people with advanced liver...
7.
Marchetti A, Pelusi S, Marella A, Malvestiti F, Ricchiuti A, Ronzoni L, et al.
Hepatology
. 2024 Mar;
80(4):816-827.
PMID: 38470216
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic and is the most rapidly rising cause of HCC. Clonal hematopoiesis of indeterminate potential (CHIP) contributes to...
8.
Graf C, DAmbrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J, et al.
JHEP Rep
. 2024 Feb;
6(3):100994.
PMID: 38357421
Background & Aims: Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection. In the present study, predictors of virologic treatment response were analyzed...
9.
Tripodi A, Primignani M, DAmbrosio R, Tosetti G, La Mura V, Lampertico P, et al.
Hepatology
. 2024 Jan;
PMID: 38214562
New global laboratory procedures mimicking the in vivo hemostasis process led to the changing paradigm of cirrhosis from the prototype of hemorrhagic diseases to a condition in which hemostasis is...
10.
Tonon M, DAmbrosio R, Calvino V, Tosetti G, Barone A, Incicco S, et al.
J Hepatol
. 2023 Dec;
80(4):603-609.
PMID: 38110003
Background & Aims: The prognostic impact of acute decompensation (AD), i.e. the development of complications that require hospitalization, has recently been assessed. However, complications of cirrhosis do not necessarily require...